BeStock  
Stocks › Biotechnology › AKTS

Aktis Oncology AKTS

US equityMarket cap rank #3242Biotechnology
$18.00 +$0.14 (+0.78%)
Pre-market · Oct 8, 8:50 am ET · After hours $18.00 0.00%
Open$17.72
Prev close$17.86
Day range$17.70 – $18.35
Volume294.1K
Market cap$1.00B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$3.38M+111.4% YoY
Operating profit-$28.90M-37.9% YoY
Net profit-$24.14M-33.6% YoY
Diluted EPS-$0.44-27.9% YoY
Free cash flow-$21.85M-23.3% YoY
Operating cash flow-$20.59M

Revenue, last 8 quarters

$0.0Dec '23$933.0KDec '24$1.4MMar '25$1.6MJun '25$1.6MSep '25$1.9MDec '25$3.2MMar '26$3.4MJun '26

Net profit, last 8 quarters

$-8.4MDec '23$-12.1MDec '24$-15.0MMar '25$-18.1MJun '25$-15.5MSep '25$-15.1MDec '25$-18.3MMar '26$-24.1MJun '26

Diluted EPS by quarter

-0.24Dec '23-0.35Dec '24-0.43Mar '25-0.34Jun '25-0.30Sep '25-0.29Dec '25-0.38Mar '26-0.44Jun '26

Free cash flow by quarter

$-7.8MDec '23$-15.0MDec '24$-19.4MMar '25$-17.7MJun '25$-17.2MSep '25$-19.4MDec '25$-26.1MMar '26$-21.8MJun '26

Annual revenue

$0.0FY22$0.0FY23$1.5MFY24$6.5MFY25

Profitability & balance sheet

Operating margin-866.6%
Net margin-727.0%
Return on equity-15.1%
Return on assets-13.1%
Return on invested capital-17.6%
Current ratio16.33
Liabilities / assets13.0%
Cash & investments$517.32M
Total debt$9.76M
Net cash (debt)$507.56M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $3.38M $3.23M $6.50M $1.87M $1.58M
Total Operating Revenue $3.38M $3.23M $6.50M $1.87M $1.58M
Operating Expense $32.28M $25.93M $81.18M $19.25M $19.78M
Selling and Admin Expenses $6.40M $5.34M $12.60M $2.51M $3.06M
-General & Admin Expense $6.40M $5.34M $12.60M $2.51M $3.06M
Research & Development $25.28M $20.04M $67.45M $16.49M $16.47M
Depreciation & Amortization & Depletion $599,000.00 $556,000.00 $1.13M $242,000.00 $254,000.00
-Depreciation & Amortization $599,000.00 $556,000.00 $1.13M $242,000.00 $254,000.00
Operating Profit -$28.90M -$22.71M -$74.68M -$17.38M -$18.20M
Net Non-Operating Interest Income (Expense) $4.77M $4.38M $11.01M $2.25M $2.68M
Non-Operating Interest Income $4.77M $4.38M $11.01M $2.25M $2.68M
Other Income (Expense) -$10,000.00 -$3,000.00 -$56,000.00 -$11,000.00 -$12,000.00
Other Non-Operating Income (Expenses) -$10,000.00 -$3,000.00 -$56,000.00 -$11,000.00 -$12,000.00
Pretax Profit -$24.14M -$18.33M -$63.73M -$15.14M -$15.53M
Net Profit -$24.14M -$18.33M -$63.73M -$15.14M -$15.53M
Profit from Continuing Operations -$24.14M -$18.33M -$63.73M -$15.14M -$15.53M
Net Income to Parent Company -$24.14M -$18.33M -$63.73M -$15.14M -$15.53M
Net Income to Common Stockholders -$24.14M -$18.33M -$63.73M -$15.14M -$15.53M
Basic EPS -$0.44 -$0.38 -$1.21 -$0.29 -$0.30
Diluted EPS -$0.44 -$0.38 -$1.21 -$0.29 -$0.30

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $557.60M $576.80M $264.89M $264.89M $279.04M
Total Current Assets $524.54M $543.94M $230.31M $230.31M $249.42M
Cash and Cash Equivalents & Short-Term Investments $517.32M $538.48M $226.79M $226.79M $246.22M
-Cash and Cash Equivalents $82.49M $371.63M $37.78M $37.78M $180.25M
-Short Term Investments $434.83M $166.85M $189.00M $189.00M $65.97M
Other Current Assets $7.22M $5.46M $3.52M $3.52M $3.20M
Total Non-Current Assets $33.06M $32.86M $34.58M $34.58M $29.62M
Net PPE $28.20M $28.11M $27.25M $27.25M $24.30M
-Gross PPE $35.27M $34.31M $32.79M $32.79M $29.15M
-Accumulated Depreciation -$7.08M -$6.20M -$5.55M -$5.55M -$4.85M
Other Non-Current Assets $4.86M $4.75M $7.33M $7.33M $5.32M
Total Liabilities $72.76M $70.69M $411.03M $411.03M $411.43M
Total Current Liabilities $32.13M $27.91M $31.24M $31.24M $26.91M
Payables $2.53M $1.23M $1.74M $1.74M $2.36M
-Accounts Payable $2.53M $1.23M $1.74M $1.74M $2.36M
Current Accrued Expenses $8.19M $5.05M $4.96M $4.96M $4.28M
Short-Term Debt and Capital Lease Obligation $1.48M $1.43M $1.32M $1.32M $1.37M
-Current Capital Lease Obligation $1.48M $1.43M $1.32M $1.32M $1.37M
Current Deferred Liabilities $17.34M $18.96M $18.66M $18.66M $16.08M
Total Non-Current Liabilities $40.63M $42.78M $379.80M $379.80M $384.52M
Long Term Debt and Capital Lease Obligation $9.76M $10.15M $10.23M $10.23M $10.50M
-Long Term Capital Lease Obligation $9.76M $10.15M $10.23M $10.23M $10.50M
Non-Current Deferred Liabilities $30.87M $32.63M $36.16M $36.16M $40.61M
Convertible preferred securities $0.00 $0.00 $333.41M $333.41M $333.41M
Total Equity $484.84M $506.11M -$146.15M -$146.15M -$132.39M
Stockholders' Equity $484.84M $506.11M -$146.15M -$146.15M -$132.39M
Capital Stock $5,000.00 $5,000.00 $0.00 $0.00 $0.00
-Common Stock $5,000.00 $5,000.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $684.61M $681.23M $10.37M $10.37M $9.02M
Retained Earnings -$199.03M -$174.89M -$156.56M -$156.56M -$141.43M
Gains/Losses Not Affecting Retained Earnings -$745,000.00 -$241,000.00 $42,000.00 $42,000.00 $16,000.00

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$20.59M -$24.24M -$64.13M -$15.24M -$15.22M
Net cash flow from continuing operations -$20.59M -$24.24M -$64.13M -$15.24M -$15.22M
Net Income from Continuing Operations -$24.14M -$18.33M -$63.73M -$15.14M -$15.53M
Depreciation & Depletion & Amortization $879,000.00 $652,000.00 $2.33M $695,000.00 $598,000.00
Change in Working Capital $489,000.00 -$9.06M -$3.23M -$1.19M -$820,000.00
-Change in Receivables -$144,000.00 -$1.11M $1.03M $804,000.00 $257,000.00
-Change in Prepaid Assets -$1.62M -$828,000.00 -$872,000.00 -$1.13M $298,000.00
-Change in Payables and Accrued Expense $5.50M -$1.89M $2.16M $903,000.00 -$448,000.00
-Change in Other Current Assets $488,000.00 -$1.69M $1.35M $417,000.00 -$38,000.00
-Change in Other Current Liabilities -$350,000.00 -$327,000.00 -$1.40M -$317,000.00 -$309,000.00
-Change In Other Working Capital -$3.38M -$3.23M -$5.50M -$1.87M -$580,000.00
Net cash flow from investing -$268.71M $20.54M $65.96M -$126.46M $85.23M
Net Cash Flow from Continuing Investing Activities -$268.71M $20.54M $65.96M -$126.46M $85.23M
Net PPE Purchase and Sale -$1.26M -$1.85M -$9.58M -$4.15M -$2.00M
Net Investment Purchase and Sale -$267.45M $22.40M $75.55M -$122.30M $87.24M
Financing Cash Flow $156,000.00 $337.55M -$1.21M -$772,000.00 $28,000.00
Net Cash Flow from Continuing Financing Activities $156,000.00 $337.55M -$1.21M -$772,000.00 $28,000.00
Net Common Stock Issuance $0.00 $339.78M – – –
Proceeds from Stock Option Exercised $156,000.00 $30,000.00 $336,000.00 $258,000.00 $28,000.00
Net Other Financing Charges $0.00 -$2.26M -$1.55M -$1.03M $0.00
Ending Cash Balance $83.64M $372.78M $38.93M $38.93M $181.40M
Net Change in Cash -$289.14M $333.85M $625,000.00 -$142.47M $70.04M
Beginning Cash Balance $372.78M $38.93M $38.31M $181.40M $111.36M
Free Cash Flow -$21.85M -$26.10M -$73.71M -$19.40M -$17.23M
Net Preferred Stock Issuance – – $0.00 $0.00 –

Discussion

No comments yet — be the first to weigh in on AKTS.

Leave a comment

Scroll to Top